Achieving equitable access to incretin-based therapies in cardiovascular care

The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, in the management of type 2 diabetes mellitus (T2DM) and obesity has been increasingly recognized, along with signi...

Full description

Bibliographic Details
Main Authors: Tina K. Reddy, Chloé D. Villavaso, Anuhya V. Pulapaka, Keith C. Ferdinand
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:American Heart Journal Plus
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666602224000983